Skip to main content

Breadcrumb

  1. Home

CSF3R Mutation Analysis

Submitted by Anonymous (not verified) on Tue, 03/25/2025 - 15:54
  • Read more about CSF3R Mutation Analysis

inv(16), CBFB-MYH11 Translocation

Submitted by Anonymous (not verified) on Tue, 03/25/2025 - 15:54
  • Read more about inv(16), CBFB-MYH11 Translocation

CEBPA Mutation Analysis

Submitted by Anonymous (not verified) on Tue, 03/25/2025 - 15:54
  • Read more about CEBPA Mutation Analysis

BTK Inhibitor Acquired Resistance Panel

Submitted by Anonymous (not verified) on Tue, 03/25/2025 - 15:54
  • Read more about BTK Inhibitor Acquired Resistance Panel

BCR-ABL1 Non-Standard p230

Submitted by Anonymous (not verified) on Tue, 03/25/2025 - 15:54
  • Read more about BCR-ABL1 Non-Standard p230

PDGFB Rearrangement (22q13)

Submitted by Anonymous (not verified) on Tue, 03/25/2025 - 15:54
  • Read more about PDGFB Rearrangement (22q13)

MYC Amplification for Angiosarcoma

Submitted by Anonymous (not verified) on Tue, 03/25/2025 - 15:54
  • Read more about MYC Amplification for Angiosarcoma

CD4/CD8 Ratio for BAL

Submitted by Anonymous (not verified) on Tue, 03/25/2025 - 15:54
  • Read more about CD4/CD8 Ratio for BAL

Claudin 18 FDA (VYLOY®) for Gastric/GEJ Adenocarcinoma

Submitted by Anonymous (not verified) on Tue, 03/25/2025 - 15:54
  • Read more about Claudin 18 FDA (VYLOY®) for Gastric/GEJ Adenocarcinoma

NRAS Mutation Analysis by PCR

Submitted by Anonymous (not verified) on Tue, 03/25/2025 - 15:54
  • Read more about NRAS Mutation Analysis by PCR

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • …
  • Next page Next
  • Last page Last
Subscribe to